EUVIMEDEUVIMED entdecken
Crossref

Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor

Arsaniouss Gars, Abeeha Khan, Sophia Kim, Caleigh Dodge, Harmandeep Tinna, Zhao Li iD, Anisha Gupta iD

Journal of Basic and Clinical Physiology and Pharmacology · 04.11.2026

DOI: 10.1515/jbcpp-2026-0265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, online erschienen am 04.11.2026. Verfasst von Arsaniouss Gars und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Saint Joseph, West Hartford, CT, USA. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bexagliflozin, approved in the United States in 2023, is the fifth selective sodium-glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes mellitus (T2DM). Unlike other class members, it lacks an event-driven cardiovascular outcomes trial (CVOT) and trials with hard kidney or heart failure endpoints. This narrative mini-review separates bexagliflozin-specific evidence from class benefits. PubMed and Google Scholar were searched for English-language articles (January 2009–June 2026) using “bexagliflozin,” “Brenzavvy,” and “SGLT2 inhibitor,” plus prescribing information and pivotal class trials. Randomized trials and meta-analyses were prioritized. Bexagliflozin reduced glycated hemoglobin (HbA 1c ), body weight, and systolic blood pressure vs. placebo and was noninferior to sitagliptin, glimepiride, and, in one 24-week trial, dapagliflozin for HbA 1c . In stage 3a/3b chronic kidney disease, it reduced albuminuria by 20.1 % vs. placebo, a surrogate finding. A cardiovascular safety trial and meta-analysis excluded excess cardiovascular risk but were not powered for benefit. Adverse events were consistent with the class. Bexagliflozin is an effective glucose-lowering drug, but its cardiovascular, kidney, and heart failure benefits remain unproven and cannot be assumed from class data. Outcome-proven agents are preferred for cardiorenal protection. An adequately powered CVOT and hard kidney endpoint trials are the key research priorities.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorbexagliflozincardiovascular outcomeschronic kidney diseasedapagliflozintype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Saint Joseph, West Hartford, CT, USA.
  • Avon High School, Avon, CT, USA.
  • Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Zhao Li, Anisha Gupta

Zitieren

APA

Gars, A., Khan, A., Kim, S., Dodge, C., Tinna, H., Li, Z., & Gupta, A. (2026). Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor. Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2026-0265

Vancouver

Gars A, Khan A, Kim S, Dodge C, Tinna H, Li Z, et al. Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor. Journal of Basic and Clinical Physiology and Pharmacology. 2026. doi:10.1515/jbcpp-2026-0265

BibTeX
@article{Gars2026,
  author = {Gars, Arsaniouss and Khan, Abeeha and Kim, Sophia and Dodge, Caleigh and Tinna, Harmandeep and Li, Zhao and Gupta, Anisha},
  title = {Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2026},
  doi = {10.1515/jbcpp-2026-0265}
}
Kostenlos starten →